Novuson Surgical, a Bothell, WA based medical device company, has secured funding from HOYA Corporation to finalize development for the UltraStat 3mm Vessel Sealer / Divider using Direct Therapeutic Ultrasound (DTU)
| BOTHELL, Wash., May 28, 2019 /PRNewswire/ -- Novuson Surgical, a Bothell, WA based medical device company, has secured funding from HOYA Corporation to finalize development for the UltraStat 3mm Vessel Sealer / Divider using Direct Therapeutic Ultrasound (DTU). DTU is a novel approach using a therapeutic modality of ultrasound in the first substantive innovation in advanced energy surgical devices in decades. The UltraStat is applicable in Urologic, Pediatric, Gynecologic, Bariatric, Trauma and other surgical specialties. “We are excited to partner with HOYA Corporation, their funding will provide necessary capital to finalize our commercial development enabling Novuson to submit our launch product, the UltraStat 3mm Mini LS, for our first 510k Clearance with the FDA by the end of this year,” said Stuart B. Mitchell, PhD, CEO & Founder of Novuson. “This investment into Novuson Surgical demonstrates HOYA’s committed involvement in the development of novel laparoscopic medical devices. We look forward to working with the Novuson team to improve clinical outcomes for patients with this advancement in ultrasonic laparoscopic devices,” said Rubal Bedi, Global Head, Vice-President of Corporate Venture Capital. As part of the investment, James M. Kaiser, Director of Corporate Venture Capital will be joining Novuson as a board member. About Novuson Surgical: About Hoya: Contact: Shane D. Cerrato, Novuson Surgical, Inc., EVP of Business Development, T: +1.916.803.6487, 425.481.7165, scerrato@novuson.com or Stuart B Mitchell, Novuson Surgical, Inc., CEO, T: 425.238.6227, sbmitchell@novuson.com.
SOURCE Novuson Surgical |
View original content:
